Follicular lymphoma, one of the most common types of lymphatic system tumors, was long considered an incurable disease that could only be controlled. However, the results of 15 years of follow-up of patients in the S0016 clinical trial have led oncologists to reconsider that view.
The study included 531 patients with previously untreated advanced disease. They received first-line therapy based on the CHOP regimen — a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone — together with immunotherapy. The analysis showed that about 70% of patients were alive 15 years after treatment began. At the same time, a special statistical “cure modeling” approach made it possible to estimate the share of people whose risk of relapse had become comparable to that of healthy people of the same age. According to the researchers’ calculations, about 42% of patients fell into this category.
Another important result concerned relapse patterns. During the first five years after treatment, the risk of the disease returning was about 6.8%, but after 15 to 20 years it fell to 0.6%. This suggests that the likelihood of relapse gradually decreases the longer remission lasts.
The authors believe the data are changing how follicular lymphoma is assessed. If the disease was previously viewed as chronic and incurable, now there is reason to speak of potential cure in some patients after standard chemoimmunotherapy. For patients, this means not only fewer checkups, but also something psychologically important: the chance one day to stop living in expectation of the next relapse.
